Spark Therapeutics — Investor Presentation (January 2019)
32 slides from Spark Therapeutics's investor presentation, Jan 7, 2019
Slide 1: Corporate Overview January 2019
Corporate Overview January 2019 1 Investor communication only: Not for use in promotion
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s product and product candidates, including LUXTURNA® (voretigene neparvovec-rzyl), SPK-7001, SPK-
Slide 3: Spark is the only company with a proven track record in gene therapies
Spark is the only company with a proven track record of discovering, developing and delivering gene therapies to patients LUXTURNA is the first and only gene therapy for a genetic disease available in both US + EU 75 vials shipped during 2018 validating strategic capabilities in gene therapy marke
Slide 4: Spark's first years: Building unique competencies
Spark’s first 5 years: Building unique competencies in the the discovery, development and delivery of gene therapies4 Investor communication only: Not for use in promotion
Slide 5: Spark's four areas of unique competencies
Spark’s four areas of unique competencies have allowed us to turn the potential of gene therapy into a sustainable portfolio Target selection and Commercial and scalable AAV vector optimization AAV manufacturing Regulatory innovation and Gene therapy market precedent-setting approvals development an
Slide 6: Four areas of unique competencies: Discover
Spark’s leadership in AAV gene therapy has created four areas of unique competencies across the gene therapy value chain DISCOVER Target selection and AAV vector Commercial and scalable AAV optimization manufacturing Regulatory innovation and Gene therapy market precedent-setting approvals developme
Slide 7: Discover: Spark's integrated translational research capabilities
Discover: Spark’s fully integrated translational research capabilities, established immunology platform and gene therapy expertise Immunology Preclinical Transgene Vector and novel program engineering optimization technologies execution platform ● Transgene ● Tailoring of vector ● Deep understanding
Slide 8: Four areas of unique competencies: Develop
Spark’s leadership in AAV gene therapy has created four areas of unique competencies across the gene therapy value chain DEVELOP Target selection and Commercial and scalable AAV vector optimization AAV manufacturing Regulatory innovation and Gene therapy market precedent-setting approvals developmen
Slide 9: Develop: AAV manufacturing capabilities inspected and cleared
Develop: Spark’s unparalleled AAV manufacturing capabilities have been inspected and cleared by regulatory agencies and partners Established adherent manufacturing process Successfully implemented commercial-scale and capabilities suspension manufacturing capabilities Purpose-built, multi-suite, i
Slide 10: Develop: Precedent-setting filings in the U.S. and Europe
Develop: Spark has led successful and precedent-setting filings for a gene therapy product in both the U.S. and Europe FDA-approved labeling for LUXTURNA Provides genetic indication without regard to phenotypic diagnosis No FDA-imposed upper age limit Eligibility of appropriate patients with t
Slide 11: Four areas of unique competencies: Deliver
Spark’s leadership in AAV gene therapy has created four areas of unique competencies across the gene therapy value chain DELIVER Target selection and AAV vector Commercial and scalable AAV optimization manufacturing Regulatory innovation and Gene therapy market precedent-setting approvals developmen
Slide 12: Deliver: U.S. LUXTURNA market development and commercialization
Deliver: U.S. LUXTURNA market development + commercialization model is overcoming challenges with gene therapy adoption Gene therapy market development imperatives successfully implemented Continued focus Operationalize Secure coverage Enable treatment of Find additional ocular gene therapy through
Slide 13: Spark's next years: Creating a portfolio of gene therapies
Spark’s next 5 years: Creating a portfolio of gene therapies across multiple therapeutic areas 13 InvestorInvestor communicationcommunication only:only: NotNot forfor useuse inin promotionpromotion
Slide 14: Learnings guide portfolio strategy and execution
Learnings derived from building Spark’s four areas of unique competencies help guide portfolio strategy and execution Target selection and Commercial and scalable AAV vector optimization AAV manufacturing Regulatory innovation and Gene therapy market precedent-setting approvals development and acces
Slide 15: Spark's ocular strategy leverages LUXTURNA's track record
Spark’s ocular strategy leverages LUXTURNA’s track record Investigational SPK-7001 for Investigational Stargardt LUXTURNA Choroideremia disease program Development + regulatory learnings: To study safety, initiated 2-year Phase Most common form of inherited 1/2 trial in 10 participants with la
Slide 16: Liver-directed platform broadened into lysosomal storage disorders
Spark’s liver-directed platform is being broadened beyond hemophilia into lysosomal storage disorders (LSDs) Secretion of therapeutic protein into Secretion of protein for uptake into tissue plasma Proof-of-concept with investigational Preclinical proof-of-concept with SPK-9001 and SPK-8011 in h
Slide 17: Preclinical proof-of-concept for delivering AAV to the CNS
Preclinical proof-of-concept for delivering AAV to the CNS, creating potential applicability of gene therapies to a broad range of neurodegenerative disorders Secretion of therapeutic proteins into the Intracellular knockdown of mRNA to CSF from ependymal cells reduce levels of toxic proteins Prec
Slide 18: Spark portfolio today: Pipeline advancing into later stages
Spark portfolio today: Pipeline advancing into later stages as well as into new therapeutic areas and delivery to new tissues Candidate optimization Discovery / IND-enabling Phase 1/2 Phase 3 Approval RETINAL DELIVERY / INHERITED RETINAL DISEASES LUXTURNA (voretigene neparvovec-rzyl): IRD due to bia
Slide 19: Leadership in gene therapy for hemophilia
Demonstrated leadership in applying gene therapy technology to the potential treatment of hemophilia19 InvestorInvestor communication communication only: only: Not Not for for use use in in promotion promotion
Slide 20: Objectives for optimized investigational gene therapies for hemophilia
Objectives for developing optimized investigational gene therapies for hemophilia Safety Efficacy ● Utilize the lowest effective dose to ● All patients achieve and maintain reduce safety risks clinically meaningful improvements ● Restore hemostasis by leveraging ─ Dramatic reduction in bleeds normal
Slide 21: SPK-8011 preliminary Phase 1/2 safety profile
Investigational SPK-8011 preliminary Phase 1/2 safety profile ● Cumulative follow-up of 9.7 patient years as of ASH data cutoff on November 2, 2018 ● No deaths, no FVIII inhibitor development ● 1 SAE – subject with elevated transaminases elective admission to hospital for IV steroid administration f
Slide 22: SPK-8011: Near elimination of bleeds and infusions
Preliminary SPK-8011 Phase 1/2 data in hemophilia A: Near elimination of bleeds and infusions for first 12 participants 94% reduction in observed bleeds beginning 95% reduction in FVIII consumption beginning 4 4 weeks after vector infusion weeks after vector infusion Prior 1 year Beginning 4 weeks P
Slide 23: SPK-8011: Persistent, stable FVIII activity
Preliminary SPK-8011 Phase 1/2 data in hemophilia A: Persistent, stable FVIII activity seen in first two cohort participants out >1 year 5e11 vg/kg dose cohort exhibiting persistent and 1e12 vg/kg dose cohort exhibiting persistent and stable FVIII activity out over 1.5 years at last read stable FVII
Slide 24: Next steps for hemophilia A program
Next steps for hemophilia A program Expanding Phase 1/2 study of investigational SPK-8011 with two modifications: – Dose additional participants with material made from suspension process – Apply standardized prophylactic steroid regimen Continue to execute on Phase 3 run-in study – Multinationa
Slide 25: AAV liver-directed platform applied to Pompe disease
Applying AAV liver-directed gene therapy platform to the development of investigational therapy for Pompe disease25 InvestorInvestor communicationcommunication only:only: NotNot forfor useuse inin promotionpromotion
Slide 26: Objectives for gene therapies for Pompe disease
Objectives for developing optimized investigational gene therapies for Pompe disease Goals for gene therapy Current treatment paradigm vs. Currentgene therapy treatment (Illustrative) paradigm Safe, sustained, long-term expression at therapeutic levels without the troughs that SoC SoC SoC SoC SoC
Slide 27: SPK-3006 for Pompe disease: preclinical data package
Investigational SPK-3006 for Pompe disease: Robust preclinical data package and IND-enabling studies support filing IND/CTA in 2Q19 SPK-3006 is an AAV gene therapy expressing a novel, modified form of GAA (secGAA) engineered for efficient secretion into plasma ─ Early evidence of reduced immunogen
Slide 28: Proof of concept in CNS-directed gene therapy
Proof of concept in CNS-directed investigational gene therapy 28 InvestorInvestor communicationcommunication only:only: NotNot forfor useuse inin promotionpromotion
Slide 29: SPK-1001 for CLN2 disease: IND-enabling work
Investigational SPK-1001 for CLN2 disease: IND-enabling work complete in 1H19; expanding applicability of Spark’s gene therapy platform to neurodegenerative diseases and delivery to the CNS CLN2 disease is a fatal neurodegenerative TPP1 expression levels from GLP tox study show disease affecting c
Slide 30: SPK-miHTT for Huntington's: PoC data
Investigational SPK-miHTT for Huntington’s: PoC data generated in multiple species to support protein knockdown approach Huntington’s disease is a fatal neurodegenerative disorder HTT Protein Normal Gene Disease pathology is caused by an expansion in CAG 10 – 27 repeats trinucleotide repeats in
Slide 31: What to expect in 2019
What to expect in 2019 31 InvestorInvestor communicationcommunication only:only: NotNot forfor useuse inin promotionpromotion
Slide 32: 2019 key catalysts
2019 key catalysts Candidate optimization Discovery / IND-enabling Phase 1/2 Phase 3 Approval RETINAL DELIVERY / INHERITED RETINAL DISEASES LUXTURNA (voretigene neparvovec-rzyl): IRD due to biallelic RPE65 mutations (US) LUXTURNA (voretigene neparvovec): IRD due to biallelic RPE65 mutations (EU) SPK
Spark Therapeutics — Investor Presentation (January 2019) on 6ix